CervoMed Inc
CRVO
Get informed when a big investor buys or sells
+ FollowMarket Cap$22.5M
Close$
$0.91
63.7% downside
Current Fair Value
63.7% downsideOvervalued by 63.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $22.50 Million |
|---|---|
| Enterprise Value | $36,110.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.98 |
| Beta | -4.31 |
| Outstanding Shares | 10,244,516 |
Return
| Return on Equity | -132.18% |
|---|---|
| Return on Assets | -116.76% |
| Return on Invested Capital | -121.90% |
Valuation & Multiples
| P/E Ratio | -0.76 |
|---|---|
| PEG | -15.12 |
| Price to Sales | - |
| Price to Book Ratio | 1.26 |
| Enterprise Value to Revenue | 0.11 |
| Enterprise Value to EBIT | 0 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-0.87
Average shareholder expectationRevenue Estimate
$50,000
Average shareholder expectationNext Earnings Call
Expected Date
November 6, 2026
EPS Estimate
$-0.53
Average shareholder expectationRevenue Estimate
$50,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 17.05%▼ 2.06% |
|---|---|
| Total Invested | $5.42M▼ 22.31% |
| Investors Holding | 37▲ 1.00% |
ESG Score
No data
About CervoMed Inc
18 employeesdiffusion pharmaceuticals is a clinical stage company focused on improving the effectiveness of standard-of-care therapies for life-threatening treatment-resistant solid cancerous tumors, without adding harmful side effects. the company ...